Early clinical data on psilocybin in anorexia point Compass to potential new opportunity

Compass Pathways has early evidence that its psilocybin therapy can improve outcomes in people with anorexia nervosa. Working with anorexia expert Walter Kaye, M.D., the British biotech showed 40% of subjects in the small study experienced clinically significant reductions in eating disorder psychopathology after a single dose of the active ingredient in magic mushrooms.

error: Content is protected !!